Tirzepatide and semaglutide are both prescription GLP-1 receptor agonists used for medically supervised weight loss. The key difference: semaglutide activates one gut-hormone pathway (GLP-1), while tirzepatide activates two (GIP and GLP-1). In clinical trials, tirzepatide produced greater average weight loss, but the right choice depends on your biology, tolerability, and goals.
Tirzepatide vs Semaglutide at a Glance
| Semaglutide | Tirzepatide | |
|---|---|---|
| Drug class | GLP-1 receptor agonist | Dual GIP / GLP-1 receptor agonist |
| FDA-approved for weight loss | June 2021 | November 2023 |
| Dosing | Once-weekly subcutaneous injection | Once-weekly subcutaneous injection |
| Most common side effects | Nausea, diarrhea, constipation, vomiting | Nausea, diarrhea, constipation, vomiting |
| Track record | Longer (approved first, more real-world data) | Shorter, but rapidly expanding |
What Semaglutide and Tirzepatide Have in Common
Both drugs are once-weekly subcutaneous injections that mimic gut hormones to reduce appetite, slow gastric emptying, and improve insulin response. The dose is gradually escalated over several weeks to let the body adjust. Each is FDA-approved for chronic weight management in adults with obesity, or with overweight plus at least one weight-related condition.
Either drug works best as part of a structured program: candidacy screening, dose titration, side-effect management, nutrition support, and resistance training to protect muscle mass during weight loss.
The Key Mechanism Difference: One Pathway vs Two
Semaglutide is a single-agonist drug that activates the GLP-1 (glucagon-like peptide-1) receptor. GLP-1 activation reduces appetite, slows digestion, and improves blood sugar control.
Tirzepatide is a dual-agonist drug that activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. The combined activation appears to produce a larger metabolic effect, which is the leading explanation for tirzepatide's stronger trial results.
How Much Weight Do People Lose on Each?
STEP-1 (semaglutide): 1,961 adults received once-weekly semaglutide 2.4 mg or placebo for 68 weeks. The semaglutide group lost an average of 14.9% of body weight vs 2.4% on placebo. About 86% lost at least 5%, and roughly half lost 15% or more. Published in NEJM (2021).
SURMOUNT-1 (tirzepatide): 2,539 adults received tirzepatide at 5 mg, 10 mg, 15 mg, or placebo for 72 weeks. Mean weight loss came in at 16.0% (5 mg), 21.4% (10 mg), and 22.5% (15 mg), vs 2.4% on placebo. Published in NEJM (2022).
SURMOUNT-5 (head-to-head): Over 72 weeks, tirzepatide produced an average 20.2% body weight loss vs 13.7% for semaglutide 2.4 mg.
Outside of trial conditions, real-world averages are typically lower. A 2024 analysis of insurance claims data found average 1-year weight loss of about 14.1% for semaglutide and 16.5% for tirzepatide, partly reflecting adherence and dosing patterns in routine clinical practice. Individual results vary based on dose, adherence, biology, and how the protocol is managed.
Are the Side Effects Different?
The side-effect profiles are similar. The most common adverse events in both trials were nausea, diarrhea, constipation, vomiting, and abdominal discomfort, mostly mild to moderate and concentrated during the dose-escalation phase.
Both medications carry boxed warnings related to thyroid C-cell tumors and are contraindicated for patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Real-world tolerability depends heavily on titration speed. A slower, more careful ramp almost always means fewer GI side effects.
Who Might Choose Semaglutide
- Patients who want the medication with the longer track record
- Patients sensitive to GI side effects who want a gentler dose-escalation
- Patients with weight loss goals in the 10–15% range
- Patients who have previously tolerated semaglutide well
Who Might Choose Tirzepatide
- Patients pursuing greater average weight loss, especially at higher starting BMIs
- Patients with insulin resistance, prediabetes, or type 2 diabetes who may benefit from the dual mechanism
- Patients who have plateaued on semaglutide
- Patients who tolerate GLP-1 medications well and want the strongest available option
How We Choose Between Them at Defiant
Every Custom GLP-1 Protocol starts with bloodwork, a 3D body composition scan, and a provider consultation. From there, we build a protocol around your biology: semaglutide, tirzepatide, or starting with one and transitioning to the other. Dosing is titrated based on response and tolerability, not a fixed schedule.
Defiant is based in Lisle, IL, serving Naperville, Downers Grove, Wheaton, Bolingbrook, Lombard, and the rest of the Chicago western suburbs. Virtual consultations are available for patients outside the immediate area.
For deeper detail on each medication, see our tirzepatide page and semaglutide page. For the full program overview, visit medical weight optimization. For how peptides fit into broader recovery and performance, see peptide therapy.
- Both medications are once-weekly subcutaneous injections FDA-approved for chronic weight management.
- Semaglutide activates one pathway (GLP-1). Tirzepatide activates two (GIP and GLP-1).
- In trials: semaglutide averaged 14.9% body weight loss (STEP-1, 68 weeks). Tirzepatide averaged 22.5% on the highest dose (SURMOUNT-1, 72 weeks).
- Side-effect profiles are similar — mostly mild-to-moderate gastrointestinal symptoms during dose escalation.
Right Medication. Right Dose. Built Around Your Biology.
Custom GLP-1 protocols start at $295/mo and include medication, provider oversight, weekly nurse check-ins, and monthly body composition scans. Members save 20%.
References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. NEJM (STEP-1)
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. NEJM (SURMOUNT-1)
- U.S. Food and Drug Administration. FDA approves new medication for chronic weight management (tirzepatide). November 8, 2023. FDA
- U.S. Food and Drug Administration. Semaglutide 2.4 mg approval for chronic weight management. June 4, 2021.
- SURMOUNT-5 head-to-head comparison of tirzepatide and semaglutide 2.4 mg, 72-week results. Eli Lilly and Company / NEJM, 2025.